Re: Overactive bladder medication adherence when medication is free to patients: C. L. Sears, C. Lewis, K. Noel, T. S. Albright and J. R. Fischer J Urol 2010; 183: 1077-1081

Comment

Cuneyd Ozkurkcugil et al. J Urol. 2010 Oct.

. 2010 Oct;184(4):1575.

doi: 10.1016/j.juro.2010.06.030. Epub 2010 Aug 21.

No abstract available

Comment on

Overactive bladder medication adherence when medication is free to patients.
Sears CL, Lewis C, Noel K, Albright TS, Fischer JR. Sears CL, et al. J Urol. 2010 Mar;183(3):1077-81. doi: 10.1016/j.juro.2009.11.026. Epub 2010 Jan 21. J Urol. 2010. PMID: 20092838

Overactive bladder medication adherence when medication is free to patients.
Sears CL, Lewis C, Noel K, Albright TS, Fischer JR. Sears CL, et al. J Urol. 2010 Mar;183(3):1077-81. doi: 10.1016/j.juro.2009.11.026. Epub 2010 Jan 21. J Urol. 2010. PMID: 20092838
Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder.
Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner T. Ivanova JI, et al. J Med Econ. 2014 Oct;17(10):741-50. doi: 10.3111/13696998.2014.941066. Epub 2014 Jul 22. J Med Econ. 2014. PMID: 25051328
Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder.
Pelletier EM, Vats V, Clemens JQ. Pelletier EM, et al. Am J Manag Care. 2009 Mar;15(4 Suppl):S108-14. Am J Manag Care. 2009. PMID: 19355799
A review of adherence to drug therapy in patients with overactive bladder.
Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, Pons ME, Kirby M, Milsom I, Vierhout M, Van Kerrebroeck P, Kelleher C. Basra RK, et al. BJU Int. 2008 Sep;102(7):774-9. doi: 10.1111/j.1464-410X.2008.07769.x. Epub 2008 Jul 4. BJU Int. 2008. PMID: 18616691 Review.
Overactive bladder: an update.
Hashim H, Abrams P. Hashim H, et al. Curr Opin Urol. 2007 Jul;17(4):231-6. doi: 10.1097/MOU.0b013e32819ed7f9. Curr Opin Urol. 2007. PMID: 17558264 Review.